Pneumonitis and concomitant bacterial pneumonia in patients receiving pembrolizumab treatment: Three case reports and literature review

RATIONALE: Pembrolizumab, a monoclonal antibody against the programmed cell death 1 (PD-1) protein, can induce a stable regression of some malignancies refractory to conventional chemotherapy. Despite such therapeutic benefits, pembrolizumab can induce immune-related adverse events, with pneumonitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Jun, Jiho, Lee, Sang-Ryung, Lee, Ji Yean, Choi, Min Joo, Noh, Ji Yun, Cheong, Hee Jin, Kim, Woo Joo, Song, Joon Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636919/
https://www.ncbi.nlm.nih.gov/pubmed/31232972
http://dx.doi.org/10.1097/MD.0000000000016158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636919/
https://www.ncbi.nlm.nih.gov/pubmed/31232972
http://dx.doi.org/10.1097/MD.0000000000016158

Ejemplares similares